Form 4: Cullinan CSO Sells 4,000 Shares Under 10b5-1 Plan

Cullinan Therapeutics' Chief Scientific Officer, Jennifer Michaelson, reported the sale of 4,000 shares of common stock at $12.30 per share, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Jennifer Michaelson, Chief Scientific Officer of Cullinan Therapeutics, Inc. (CGEM), reported a transaction.
• The transaction involved the disposition of 4,000 shares of common stock.
• The sale occurred on January 22, 2026, at a price of $12.30 per share.
• The transaction was executed pursuant to a Rule 10b5-1 trading plan established on August 7, 2025.
• Following this transaction, Michaelson beneficially owns 128,635 shares of common stock directly.

Sentiment

Score: 5

Explanation: A neutral score as this is a routine insider transaction under a pre-established 10b5-1 plan, which is generally not indicative of a strong positive or negative sentiment regarding the company's immediate prospects. It's a planned liquidity event.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces management's direct equity stake in the company.

Stakeholder Impact

• Shareholders may interpret the sale as a signal, though the 10b5-1 plan mitigates immediate concerns about opportunistic selling.

Key Dates

Recommendation

The filing reports a routine, pre-scheduled sale of shares by a Chief Scientific Officer under a 10b5-1 plan. Such transactions are typically for personal financial planning and do not usually signal a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this event. Investors should continue to hold and monitor broader company performance and market conditions.

Keywords

Cullinan Therapeutics, CGEM, Insider Trading, Form 4, Stock Sale, Jennifer Michaelson, Chief Scientific Officer, 10b5-1 Plan